Podcast Episode 1: Women’s Health
In our first episode we were joined by an amazing group of panelists to discuss women’s health and all it encompasses. We touch on topics from barriers to investment and lack of investor understanding, the glaring innovation gap and how it leaves out pregnant women in R&D, the power of partnership between clinicians and investors and so much more.
A huge thank you to panelists from GHIN and our co-investors:
• Sheetal Nariani – General Partner & CFO, Global Health Impact Network & Funds
• Dr. Janet Moore Goldman – Perinatologist, UCSF Health
• Annie Theriault – Managing Partner, Cross-Border Impact Ventures
• Megan Dover, P.Eng., MBA – Junior Partner & Co-founder, Cross-Border Impact Ventures
• Anna Neverova – Founder & CEO, Phi Networks Group
August 2024 Newsletter
Back to School and Immunizations: Latest News
As the back-to-school season approaches, it's essential to keep up with the latest in pediatric health and immunizations. In honor of National Immunization Awareness Month, this edition of our newsletter provides you with the latest industry news and updates in pediatric immunology and the entire sector. Discover new developments in vaccines, health trends, and how startups of varying sizes are tackling the problem.
July 2024 Newsletter
Tapping into a trillion dollar opportunity: closing the gender healthcare gap with Raydiant Oximetry
In this issue, we are thrilled to share the remarkable success of our portfolio company, Raydiant Oximetry. The team at Raydiant has raised an oversubscribed Series A extension round with over $7.5 million in funding.
June 2024 Newsletter
Women’s healthcare is expanding beyond reproductive health to address cardiovascular health, mental health, and chronic conditions, meeting the diverse needs of women throughout their life cycle. AI is revolutionizing the industry, transforming traditional software models and enhancing outcomes through workflow digitization, value-based care, and consumer empowerment.
Maternal and Fetal Health Company Raydiant Oximetry Secures $7.5M in Oversubscribed Series A Extension Round
Raydiant Oximetry, a clinical-stage medical device company focused on improving outcomes for mothers and babies during childbirth has closed an oversubscribed $7.5 million Series A3 extension round.
Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study
Raydiant Oximetry, Inc., a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, announces that the United States Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) of the Lumerah™ technology for an Early Feasibility Study (EFS) of pregnant women during labor and delivery.